Next Article in Journal / Special Issue
iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development
Previous Article in Journal
Neurosurgical Hyponatremia
Previous Article in Special Issue
Human iPS Cell-Derived Germ Cells: Current Status and Clinical Potential
Open AccessReview

Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells

1
Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China
2
Research Center of Heart, Brain, Hormone and Healthy Aging, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China
3
Hong Kong-Guangdong Joint Laboratory on Stem Cell and Regenerative Medicine, the University of Hong Kong and Guangzhou Institutes of Biomedicine and Health, Hong Kong SAR, China
4
Shenzhen Institutes of Research and Innovation, the University of Hong Kong, Hong Kong SAR, China
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2014, 3(4), 1105-1123; https://doi.org/10.3390/jcm3041105
Received: 31 July 2014 / Revised: 15 September 2014 / Accepted: 17 September 2014 / Published: 15 October 2014
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
The lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human cell-based platform for the study of human hereditary cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac disorders for therapeutic studies have been increasingly highlighted. In this review, the standard procedures for generating patient-specific iPSCs and the latest commonly used cardiac differentiation protocols will be outlined. Furthermore, the progress and limitations of current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail. View Full-Text
Keywords: patient-specific-iPSCs-derived cardiomyocytes; regenerative medicine; modeling of inherited cardiac disorder; drug testing; toxicology studies patient-specific-iPSCs-derived cardiomyocytes; regenerative medicine; modeling of inherited cardiac disorder; drug testing; toxicology studies
Show Figures

Graphical abstract

MDPI and ACS Style

Ng, K.-M.; Law, C.-Y.; Tse, H.-F. Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells. J. Clin. Med. 2014, 3, 1105-1123.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop